These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 19877382)

  • 21. Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer.
    Michieletto S; Saibene T; Evangelista L; Barbazza F; Grigoletto R; Rossi G; Ghiotto C; Bozza F
    Breast; 2014 Feb; 23(1):19-25. PubMed ID: 24189101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
    Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
    Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
    Dobricić J; Branković-Magić M; Filipović S; Radulović S
    Cancer Genet Cytogenet; 2010 Oct; 202(1):27-32. PubMed ID: 20804917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
    Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation of CerbB-2 to Ki-67 and P53 expressions in hormone-independent breast cancer].
    Fang Q; Wang XF
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Feb; 31(2):380-2. PubMed ID: 21354936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
    Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
    J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
    Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
    Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of nodal metastasis and prognosis of breast cancer by ANN-based assessment of tumour size and p53, Ki-67 and steroid receptor expression.
    Mojarad S; Venturini B; Fulgenzi P; Papaleo R; Brisigotti M; Monti F; Canuti D; Ravaioli A; Woo L; Dlay S; Sherbet GV
    Anticancer Res; 2013 Sep; 33(9):3925-33. PubMed ID: 24023330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.